

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549  
 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL	
OMB Number:	3235-0076
Estimated average burden hours per response:	4.00

1. Issuer's Identity

<b>CIK (Filer ID Number)</b>	<b>Previous Names</b>	None	<b>Entity Type</b>
<a href="#">0001512762</a>	BioGenerics, Inc.		<input checked="" type="checkbox"/> Corporation
<b>Name of Issuer</b>			<input type="checkbox"/> Limited Partnership
Coherus BioSciences, Inc.			<input type="checkbox"/> Limited Liability Company
<b>Jurisdiction of Incorporation/Organization</b>			<input type="checkbox"/> General Partnership
DELAWARE			<input type="checkbox"/> Business Trust
<b>Year of Incorporation/Organization</b>			<input type="checkbox"/> Other (Specify)
Over Five Years Ago			
<input checked="" type="checkbox"/> Within Last Five Years (Specify Year) 2010			
<input type="checkbox"/> Yet to Be Formed			

2. Principal Place of Business and Contact Information

<b>Name of Issuer</b>			
Coherus BioSciences, Inc.			
<b>Street Address 1</b>		<b>Street Address 2</b>	
C/O DENNIS M. LANFEAR		201 REDWOOD SHORES PARKWAY, SUITE 200	
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>	<b>Phone Number of Issuer</b>
REDWOOD CITY	CALIFORNIA	94065	(650) 649-3530

3. Related Persons

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>
Lanfeare	Dennis	M.
<b>Street Address 1</b>	<b>Street Address 2</b>	
Coherus BioSciences, Inc.	201 Redwood Shores Parkway, Suite 200	
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>
Redwood City	CALIFORNIA	94065
<b>Relationship:</b> <input checked="" type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>
Finck, M.D.	Barbara	K
<b>Street Address 1</b>	<b>Street Address 2</b>	
Coherus BioSciences, Inc.	201 Redwood Shores Parkway, Suite 200	
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>
Redwood City	CALIFORNIA	94065
<b>Relationship:</b> <input checked="" type="checkbox"/> Executive Officer <input type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Healy, M.D., Ph.D.	James	I.
Street Address 1	Street Address 2	
Sofinnova Ventures	2800 Sand Hill Road, Suite 150	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Herman	Alan	C.
Street Address 1	Street Address 2	
Coherus BioSciences, Inc.	201 Redwood Shores Parkway, Suite 200	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
<b>Relationship:</b> X Executive Officer Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Lawlis, Ph.D.	V.	Bryan
Street Address 1	Street Address 2	
c/o Coherus BioSciences, Inc.	201 Redwood Shores Parkway, Suite 200	
City	State/Province/Country	ZIP/PostalCode
Redwood City	CALIFORNIA	94065
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Richards	Christos	
Street Address 1	Street Address 2	
Levin & Company	1800 Century Park East, Suite 600	
City	State/Province/Country	ZIP/PostalCode
Los Angeles	CALIFORNIA	90067
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Satvat	Ali	J.
Street Address 1	Street Address 2	
Kohlberg Kravis Roberts & Co. L.P.	2800 Sand Hill Road, Suite 200	
City	State/Province/Country	ZIP/PostalCode
Menlo Park	CALIFORNIA	94025
<b>Relationship:</b> Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Szela	Mary	T.

<b>Street Address 1</b>	<b>Street Address 2</b>		
c/o Coherus BioSciences, Inc.	201 Redwood Shores Parkway, Suite 200		
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>	
Redwood City	CALIFORNIA	94065	
<b>Relationship:</b>	Executive Officer X Director	Promoter	

Clarification of Response (if Necessary):

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>	
Troendle, M.D.	August	J.	
<b>Street Address 1</b>	<b>Street Address 2</b>		
Medpace, Inc.	5375 Medpace Way		
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>	
Cincinnati	OHIO	95227	
<b>Relationship:</b>	Executive Officer X Director	Promoter	

Clarification of Response (if Necessary):

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>	
Viret, Ph.D.	Jean-Frederic		
<b>Street Address 1</b>	<b>Street Address 2</b>		
Coherus BioSciences, Inc.	201 Redwood Shores Parkway, Suite 200		
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>	
Redwood City	CALIFORNIA	94065	
<b>Relationship:</b>	X Executive Officer	Director	Promoter

Clarification of Response (if Necessary):

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>	
Wahlstrom	Mats		
<b>Street Address 1</b>	<b>Street Address 2</b>		
Leonard Capital, LLC	1225 Seventeenth Street, Suite 2420		
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>	
Denver	COLORADO	80202	
<b>Relationship:</b>	Executive Officer X Director	Promoter	

Clarification of Response (if Necessary):

<b>Last Name</b>	<b>First Name</b>	<b>Middle Name</b>	
Watler, Ph.D.	Peter	K.	
<b>Street Address 1</b>	<b>Street Address 2</b>		
Coherus BioSciences, Inc.	201 Redwood Shores Parkway, Suite 200		
<b>City</b>	<b>State/Province/Country</b>	<b>ZIP/PostalCode</b>	
Redwood City	CALIFORNIA	94065	
<b>Relationship:</b>	X Executive Officer	Director	Promoter

Clarification of Response (if Necessary):

#### 4. Industry Group

Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology

Insurance  
Investing  
Investment Banking  
Pooled Investment Fund  
Is the issuer registered as an investment company under the Investment Company Act of 1940?  
Yes No  
Other Banking & Financial Services  
Business Services  
Energy  
Coal Mining  
Electric Utilities  
Energy Conservation  
Environmental Services  
Oil & Gas  
Other Energy

Hospitals & Physicians  
Pharmaceuticals  
X Other Health Care  
Manufacturing  
Real Estate  
Commercial  
Construction  
REITS & Finance  
Residential  
Other Real Estate

Computers  
Telecommunications  
Other Technology  
Travel  
Airlines & Airports  
Lodging & Conventions  
Tourism & Travel Services  
Other Travel  
Other

5. Issuer Size

<b>Revenue Range</b>	<b>OR</b>	<b>Aggregate Net Asset Value Range</b>
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
Rule 505	Section 3(c)(5)	Section 3(c)(13)
X Rule 506(b)	Section 3(c)(6)	Section 3(c)(14)
Rule 506(c)	Section 3(c)(7)	
Securities Act Section 4(a)(5)		

7. Type of Filing

X New Notice Date of First Sale 2015-09-10 First Sale Yet to Occur  
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity  
Debt  
Option, Warrant or Other Right to Acquire Another Security  
Security to be Acquired Upon Exercise of Option, Warrant or  
Other Right to Acquire Security

Pooled Investment Fund Interests  
Tenant-in-Common Securities  
Mineral Property Securities  
Other (describe)

#### 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes  No

Clarification of Response (if Necessary):

#### 11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

#### 12. Sales Compensation

Recipient	Recipient CRD Number <input checked="" type="checkbox"/> None
N/A	None
(Associated) Broker or Dealer <input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number <input checked="" type="checkbox"/> None
None	None

##### Street Address 1

##### Street Address 2

N/A	N/A	
City	State/Province/Country	ZIP/Postal Code
N/A	Unknown	00000

State(s) of Solicitation (select all that apply)  
Check "All States" or check individual States All States  Foreign/non-US

#### 13. Offering and Sales Amounts

Total Offering Amount	\$9,999,980 USD	or	Indefinite
Total Amount Sold	\$9,999,980 USD		
Total Remaining to be Sold	\$0 USD	or	Indefinite

Clarification of Response (if Necessary):

#### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. \_\_\_\_\_  
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 

1
---

#### 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	<input checked="" type="checkbox"/> Estimate
Finders' Fees	\$0 USD	<input checked="" type="checkbox"/> Estimate

Clarification of Response (if Necessary):

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Coherus BioSciences, Inc.	/s/ Alan C. Mendelson	Alan C. Mendelson	Secretary	2015-09-17

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.